NCT01944527

Use of Direct-acting Antiviral to Treat HCV Recurrence After Liver Transplantation (ANRSCO23CUPILT) Infection

Cohort of Liver Transplanted Patients With Hepatitis C Virus Recurrence and Treated With Direct-acting Antiviral Agents

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 699 (actual)
• Sponsor: ANRS, Emerging Infectious Diseases · Other Government
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy, safety and tolerability of direct-acting antivirals therapy in liver transplanted patients who experienced HCV recurrence. This cohort is multicentric with constitution of biobank (plasma, serum) and the prospective collect of biological and clinical data's in the liver transplanted patients with recurrent HCV infection and treated with direct-acting anti-HCV agents.

Conditions

• HCV Recurrence
• Liver Transplantation
• Direct-acting Antiviral Agents

Timeline

• Start date: 2013-10-01
• Primary completion: 2015-12-01
• Completion: 2017-06-01
• First posted: 2013-09-17
• Last updated: 2016-02-02

Locations

1 site across 1 country: France